Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Xyphos Biosciences, Inc. engages in biotechnology business. The firm’s novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform allows new ways to mobilize and control immune cells to find and destroy specifically targeted cells throughout the body. The company was founded by David W. Martin, Jr. and James L. Knighton and is headquartered in South San Francisco, CA.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Nanjing Legend Biotechnology Co., Ltd. is a private company headquartered in Nanjing, China, that develops tumor cell immunotherapies.

Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.

They are a pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach. Our antibodies bind only to specific immunosuppressive proteins that are released from cancer cells (soluble ligands), and not to the cell surface-bound versions. This treatment is predicted to be effective towards multiple types of cancers and has safety built into the design of the drug, thereby minimizing the likelihood of unwanted side effects. Our current studies have demonstrated efficacy in repeated prostate cancer models in mice.

AvidBiotics is a biotherapeutics company deploying a proprietary biotechnology-derived technology platform that has multiple applications in life sciences. The company develops novel, non-antibody proteins used to target bacteria, virus-infected cells, and cancers. Its portfolio of therapeutic protein candidates and protein engineering platforms specifically flags virus-infected or cancerous cells for enhanced destruction by the Natural Killer and T-cells of the potent innate immunity systems and focuses on human therapeutic applications of its technologies that enable physicians to activate the immune system to target and destroy cancer cells infected by viruses with laser precision.

Shenzhen Binder Biotechnology Co., Ltd., established on 2015-06-11, Business scope includes general business items:Technical development of biological products;Technology development of biotechnology products;Sales of bioengineering products and technology transfer of research and development achievements of related projects,Technical service and technical consultation.(All of the above are related to the law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:

Cambridge University Technical Services Ltd., part of University of Cambridge, is a British company located in Cambridge. The firm provides consulting services. It was founded in 2006.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Cytoimmune Therapeutics, Inc. is an American private company located in Monrovia, CA. The firm develops and commercializes cancer immunotherapy products. It was founded in 2019 by Michael A. Caligiuri and William Michael Rosellini. Christina Marie Coughlin is the CEO, in this role since 2021.\nThe company says this about itself: CytoImmune Therapeutics is a clinical-stage immune-oncology company focused on the development and commercialization of novel cancer immunotherapy products that empower the engineered effector cells to activate the patient’s immune system against cancer cells. The company has a focus in solid tumors and is leveraging our engineered cord blood NK cells as the therapy backbone. The company’s pipeline includes the tumor-reactive NK cell platform of assets in combination with engager and monoclonal antibody therapies that target gastric, pancreatic, non-small cell lung, ovarian, and endometrial indications, among others.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Guangzhou Baiji Bio-Pharmaceutical Co., Ltd., established on 2016-09-21, Business scope includes medical research and experimental development(human stem cells,Except for genetic diagnosis and treatment technology);Sales of products produced by the company(Except for projects prohibited by national laws and regulations;Products involving licensed operation need to obtain a license before they can be operated);Biotechnology Extension Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Development Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Consulting,communication service(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Transfer Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Enterprise Management Services(Except for those involving licensed business projects);Technology Import and Export;Manufacturing of chemical preparations;Biopharmaceutical Manufacturing;

Nanjing Kaidi Medical Technology Co., Ltd., established on 2020-11-05, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;R&D and application of cell technology(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen Shuangke Biotechnology Co., Ltd., established on 2012-11-01, Business scope includes general business items:biotechnology development,technical consulting,Sales of Class I Medical Devices;Domestic Trade,Import and export of goods and technology.(law,Administrative regulations,Except for items that are subject to approval prior to registration by decision of the State Council),The licensing program is:Technology Development in Life Sciences,technical consulting;In vitro diagnostic reagents(Except special management diagnostic reagents)promotion of;Class II,Class III6840In vitro diagnostic reagents;Class II,Class III6858medical cryotherapy low temperature,Refrigeration equipment and appliances;Class II6857Disinfection and sterilization equipment and utensils;Class II6841Medical testing and basic equipment;Class II,Class III6840Clinical laboratory analysis instruments and related technical consultation;Health and wellness management consulting(Does not contain medical behavior),psychological counseling(Does not contain medical behavior);Technology development in medical devices and their fields,technical consulting;Engaged in technical consulting in the field of medicine,technology development